SCOHIA PHARMA
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Japanese bioventure developing innovative small molecule drugs for metabolic, cardiovascular, and renal diseases through a diversified pipeline and strategic collaborations.
MetabolicCardiovascularRenalEndocrineRare Diseases
Technology Platform
Small molecule drug discovery focused on novel mechanisms of action for lifestyle-related diseases, with strategy emphasizing different MOAs at each development stage and backup compounds in preclinical projects.
Opportunities
Large addressable markets in obesity, diabetes, and metabolic diseases; potential for first-in-class therapies with novel mechanisms like SSTR5 antagonism; additional partnership opportunities for Value-Added Pipeline assets.
Risk Factors
Early-stage pipeline with only one program in clinical trials; intense competition in metabolic disease space from large pharma and biotech companies; reliance on partners for development and commercialization of key assets.
Competitive Landscape
Competes in crowded metabolic disease space but differentiates through novel mechanisms like SSTR5 antagonism for endocrine disorders and quadruple agonist approach for obesity; faces competition from Novo Nordisk, Eli Lilly, and other GLP-1 developers.